18:21 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

PharmaMar reports OS data from Phase III of Aplidin for MM

PharmaMar S.A. (Madrid:PHM) reported data for the secondary overall survival (OS) endpoint from the Phase III ADMYRE trial in 255 patients with relapsed or refractory multiple myeloma (MM) evaluating Aplidin plitidepsin plus dexamethasone vs. dexamethasone...
00:13 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends against PharmaMar's Aplidin for MM

EMA's CHMP recommended against approval of Aplidin plitidepsin from PharmaMar S.A. (Madrid:PHM) to treat relapsed or refractory multiple myeloma. The committee said it will publish more information on the opinion "shortly." Chugai Pharmaceutical Co. Ltd....
23:22 , Dec 15, 2017 |  BC Extra  |  Company News

CHMP recommends basket of therapies

EMA's CHMP recommended approval of a host of therapies, including Alofisel darvadstrocel (Cx601) to treat Crohn's disease, Ozempic semaglutide (NN9924, OG217SC) to treat Type II diabetes, Herzuma biosimilar trastuzumab to treat breast and gastric cancer...